Randall Michael Giuffre - 02 Jan 2026 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Reporting relationship: Director
Issuer ticker: DMAC
Reported as of: 02 Jan 2026
Net transaction value: +$51,994
SEC form: 4
Accepted by SEC: 06 Jan 2026, 17:24:08 UTC
Prior SEC filing: 03 Jun 2025
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Scott Kellen, attorney-in-fact

Key filing fact

Randall Michael Giuffre filed Form 4 for DiaMedica Therapeutics Inc. (DMAC) on 06 Jan 2026.

Key facts

This page summarizes Randall Michael Giuffre's Form 4 filing for DiaMedica Therapeutics Inc. (DMAC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 06 Jan 2026, 17:24.

Change

Previous filing in this sequence was filed on 03 Jun 2025.
Current net transaction value: +$51,994.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001759822 Primary reporting owner

Giuffre Randall Michael

Relationship: Director
Address: 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS
Signature: /s/ Scott Kellen, attorney-in-fact
Signature date: 06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DMAC transaction

Common Stock

Award

Transaction value: $51,994
Shares: +6,175
Change %: +1.6%
Price: $8.42
Shares after: 398,587
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1

DMAC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 25,573
Date: 02 Jan 2026
Ownership: See footnote
Footnotes: F2

DMAC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 21,070
Date: 02 Jan 2026
Ownership: By Spouse

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $52,000. The deferred stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026.

Footnote F2

These voting common shares are held by 424822 Albert Ltd, of which Michael Giuffre has sole voting and dispositive power.